Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does mycophenolate mofetil decrease the recurrent acute rejection in renal transplant recipients.

Aneesh Srivastava1, Vishwajeet Singh, Devendra Kumar

  • 1Department of Urology, Nephrology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India. address-anees@sgpgi.ac.in

International Urology and Nephrology
|November 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Imaging of anorectal and perineal emergencies - a multimodality review.

Emergency radiology·2026
Same author

Inhibition of Proteus mirabilis growth through gallium-based disruption of iron and heme metabolism.

The Journal of antibiotics·2026
Same author

Role of diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient in subtyping renal cell carcinoma.

World journal of radiology·2026
Same author

Soil microorganisms in the age of plastic pollution: effects of micro- and nano-plastics on soil health.

Environmental science and pollution research international·2026
Same author

Cecoureterocele Presenting as a Urethral Mass in an Infant Female: A Rare Case Report.

Biomedicine hub·2026
Same author

Rational Design and Optimisation of CRISPR-Cas9 Delivery Systems for Targeted Genomic Transformation.

The journal of gene medicine·2026
Same journal

Systematic review and meta-analysis of randomized controlled trials: low-intensity extracorporeal shockwave therapy (Li-ESWT) for erectile dysfunction after radical prostatectomy.

International urology and nephrology·2026
Same journal

Multiparametric MRI-derived radiomic signatures enable noninvasive prediction of HER2 expression in bladder cancer.

International urology and nephrology·2026
Same journal

Does WHO/ISUP grade IV histology provide prognostic insight in chromophobe renal cell carcinoma?

International urology and nephrology·2026
Same journal

Age-stratified association between blood pressure and clinical outcomes in maintenance hemodialysis patients.

International urology and nephrology·2026
Same journal

Management and implementation of intermittent catheterisation in neurogenic lower urinary tract dysfunction: a clinical practice guideline in Germany - update 3.0.

International urology and nephrology·2026
Same journal

Interpreting short-term eGFR improvement with telitacicept in IgA nephropathy.

International urology and nephrology·2026
See all related articles

Mycophenolate mofetil (MMF) significantly reduces recurrent acute rejection in renal transplant patients. However, its high cost limits routine use in certain populations, despite comparable patient and graft survival rates.

Area of Science:

  • Nephrology
  • Immunosuppression Therapy
  • Transplant Medicine

Background:

  • Mycophenolate mofetil (MMF) is a key immunosuppressant in renal transplantation.
  • Its high cost restricts routine application in some healthcare settings.
  • The study evaluates MMF's efficacy and safety in a specific patient cohort.

Purpose of the Study:

  • To assess the effectiveness of MMF in reducing recurrent acute rejection in renal transplant recipients.
  • To compare MMF-based immunosuppression with a conventional regimen (cyclosporine, azathioprine, steroid).
  • To evaluate MMF's impact on liver function and opportunistic infections.

Main Methods:

  • A retrospective analysis of 60 renal transplant patients receiving MMF for acute vascular rejection.

Related Experiment Videos

  • MMF was used as rescue therapy, with 20 patients having co-existing chronic liver disease.
  • A control group of 60 patients received standard immunosuppression.
  • Follow-up was at least 1 year.

    • Main Results:

    • MMF group showed significantly lower recurrent acute rejection rates (18%) compared to the control group (42%).
    • Serum transaminases normalized in patients with liver disease within 3-6 months.
    • Opportunistic infection rates were higher in the MMF group (22%) versus the control group (11%).
    • MMF regimen was twice as expensive as the control.

    Conclusions:

    • MMF-based immunosuppression effectively reduces recurrent acute rejection in renal transplants.
    • The higher cost of MMF poses a barrier to its routine use in resource-limited settings.
    • One-year patient and graft survival rates were comparable between the MMF and control groups.